Abstract
Background:
With regard to the effect of calcium against colorectal cancer (CRC) and considering the key role of calcium sensing receptor (CaSR) in calcium homeostasis, this study investigated whether CaSR gene rs1801725 or A986S variant was associated with susceptibility to CRC risk.Methods:
This study was conducted as a case-control study and 303 cases with CRC and 354 controls were enrolled. All 657 subjects were genotyped for CaSR gene A986S variant using PCR-RFLP method.Results:
No significant difference was observed for the A986S variant of CaSR gene in either genotype or allele frequencies between the cases and the controls and this lack of difference remained non-significant even after adjustment for age, BMI, sex, smoking status, and family history of CRC. No evidence for the effect modification of the association A986S variant and CRC by BMI, sex, or tumor site was also observed. Furthermore, the risk of obesity in relation to the A986S variant in the controls and the cases was separately analyzed and we observed no significant difference between normal weight (BMI < 25kg/m2) and overweight/obese (BMI ≥ 25kg/m2) subjects.Conclusions:
Our findings do not support a role for effect of the CaSR gene A986S variant on CRC risk; nevertheless, this finding requires confirmation and the role of the gene variant in carcinogenesis needs to be further investigated.Keywords
Calcium Sensing Receptor Gene Colorectal Cancer RFLP Variant
1. Background
Colorectal cancer (CRC) is a major health problem and is the second leading cause of cancer-related mortality (1, 2). Previous studies have demonstrated that high calcium intake may lower the risk of colon cancer (3, 4). On the other hand, calcium sensing receptor (CaSR) which contains seven exons and belongs to the G-protein coupled receptor superfamily has a critical role in the maintenance of calcium homeostasis by modulating PTH secretion from the parathyroid glands (5). The CaSR is expressed in human colonic epithelium and colon cancer cells (6). Calcium and CaSR are well-organized controllers of colonocytes (7) and calcium by signaling through CaSR suppresses normal colonocyte proliferation. Furthermore, calcium stimulates the expression of the tumor suppressor gene E-cadherin via CaSR in colon cancer cells (8). Dysregulation of E-cadherin expression seems to be involved in progression from adenoma to carcinoma (9). Furthermore, activation of CaSR suppresses β-catenin-TCF-4 oncogenic pathway (8).
The relationship between CaSR gene polymorphisms and CRC risk has lately garnered a great deal of attention and association studies of CaSR gene A986S (rs1801725) variant have been performed to investigate its implication with CRC risk, but the results are somewhat contradictory (10-14) and the role of this gene in the etiology of CRC is still equivocal. Some studies (10, 11, 13, 14) have found no association, other investigations (12) have reported significant associations between the A986S variant and the risk of CRC.
Accordingly, these observations led we look for the possible association of the A986S (rs1801725) variant located in exon 7 of CaSR gene with CRC risk. Selection criteria for this polymorphism were based on (a) its use in previous genetic epidemiology studies (b) degree of heterozygosity (c) position in the gene (d), and functional importance.
2. Methods
2.1. Participants
The study population consisted of 303 cases with CRC and 354 controls reporting to the research institute for gastroenterology and liver diseases (RCGLD), Shahid Beheshti University of Medical Sciences. This study was conducted as a case-control study and all the subjects were recruited from patients who were under going colonoscopy either because of various gastrointestinal symptoms or because of they were considered high risk for CRC. Cases were the patient with positive pathologic report for CRC, and eligibility criteria for control subjects included no individual history of colorectal malignancy or polyps (including adenomatous and other polyps). All patients and controls were Iranian and genetically unrelated. Before subject’s colonoscopy, self administration had been used to collect the information about their demographic, anthropometric, and clinical characteristics. The present study was approved by the ethical committee of the institute and all study participants were informed about the aims of the study and gave written consents. Body mass index (BMI) of each subject was calculated as body weight divided by height squared (kg/m2).
2.2. Genotype Analysis
Blood samples from all the subjects were collected in tubes containing EDTA as an anticoagulant and store at 4°C. Genomic DNA was purified from peripheral blood leucocytes using standard “phenol chloroform” method. In this study, genotyping was done by using PCR-RFLP method. Also, genotyping of the CaSR gene was performed by investigators who were blinded to the participants’ clinical data. The A986S (rs1801725) variant was evaluated by a PCR that amplified a 269 bp fragment using a forward (5’-CTGAGCTTTGATGAGCCTCAGAAGGAC-3’) and a reverse (5’-CACTGATGACAAGCTCTGTGAACTGGA-3’) primer (15). The PCR reaction was run at 93°C for 10 minutes followed by 35 cycles of 93°C for 45s, 63°C for 30s, 72°C for 45 seconds, and final extension at 72°C for 10 minutes. The PCR products were digested overnight with restriction enzyme Hin1I (Fermentas, Leon-Rot, Germany) at 37°C and the RFLP products were run on 3% agarose gel, and stained with ethidium bromide for visualization under UV light. CaSR genotypes of each subject were identified according to the digestion pattern and alleles according to the absence (“T”) or presence (“G”) of the Hin1I site. Hin1I digestion reveals genotypes denoted TT (269 bp), GT (269, 241 bp and 28 bp), or GG (241 bp and 28 bp). The concordance of genotyping was confirmed by duplicate analysis of approximately 10% of the samples and DNA sequencing of approximately 3% of the samples that all of them were selected randomly (all results were accurate).
2.3. Statistical Methods
We calculated differences in demographic or anthropometric factors using t-test or χ2 test when appropriate. Testing Hardy-Weinberg equilibrium for the CaSR gene A986S variant among cases and controls, separately, and comparisons of the distribution of the allele frequencies between the groups were performed using the χ2 test. Comparisons of the distribution of the genotype frequencies between the different groups were performed using the logistic regression. Logistic regression analysis was also used to adjust for confounders such as age, BMI, sex, smoking status, and family history of CRC. The odds ratios (OR) are given with the respective 95% confidence intervals (95% CI). SPSS statistical package (version 15.0; SPSS Inc. Chicago, IL, USA) was used to analyze the data. In all statistical tests, a P value of less than 0.05 was considered to indicate statistical significance.
3. Results
3.1. Clinicopathological Analysis
Selected characteristics of the study population and their statistical significance are summarized in Table 1. On average, cases with CRC were older (P < 0.001) and less likely to use NSAIDs (P < 0.001) when compared with their control counterparts. However, there were no significant differences between the cases with CRC and the controls in terms of BMI, sex, smoking status, and family history of colorectal cancer.
Selected Characteristics of the Study Subjectsa
| Variables | Controls (N = 354) | Cases (N = 303) | P Value |
|---|---|---|---|
| Age, y | 43.9 (16.7) | 55.7 (12.5) | < 0.001 |
| BMI, kg/m2 | 25.0 (4.0) | 25.4 (4.7) | 0.216 |
| Gender | |||
| Male | 181 (51.1) | 165 (54.5) | |
| Female | 173 (48.9) | 138 (45.5) | 0.395 |
| Smoking history | |||
| No | 294 (83.0) | 247 (81.5) | |
| Former | 48 (13.6) | 37 (12.2) | |
| Current | 12 (3.4) | 19 (6.3) | 0.207 |
| Regular NSAID use | |||
| No | 283 (79.9) | 289 (95.4) | |
| Yes | 71 (20.1) | 14 (4.6) | < 0.001 |
| Family history of colorectal cancer | |||
| No | 308 (87.0) | 264 (87.1) | |
| Yes | 46 (13.0) | 39 (12.9) | 0.963 |
| Tumor site | |||
| Colon | - | 195 (64.4) | |
| Rectal | - | 108 (35.6) | - |
| Metastasis | |||
| No | - | 276 (91.1) | |
| Yes | - | 27 (8.9) | - |
| HNPCC | |||
| No | - | 282 (93.1) | |
| Yes | - | 21 (6.9) | - |
3.2. CaSR Gene A986S Variant Analysis
The distribution of genotypes and alleles of the CaSR gene A986S variant in cases with CRC and controls are provided in Table 2. None of the genotype frequency distributions for the A986S variant deviated significantly from the Hardy-Weinberg equilibrium in both cases and controls, suggesting that the alleles are in equilibrium (P > 0.05). As shown in Table 2, no significant difference was observed in genotype and allele frequencies between the cases with CRC and the controls for the A986S polymorphism. Furthermore, after adjustment for age, BMI, sex, smoking status and family history of CRC, no significant association between the polymorphism and the risk of CRC was found.
The Genotype and Allele Frequencies of Casr Gene A986S (Rs1801725) Variant in Cases with Colorectal Cancer and Controlsa
| Variant | Controls (N = 354) | Cases (N = 303) | Crude | Adjustedb | ||
|---|---|---|---|---|---|---|
| OR (95% CI) | P Value | OR (95% CI) | P Value | |||
| rs1801725 G>T | ||||||
| Genotype-wise comparison | ||||||
| GG | 215 (60.7) | 181 (59.7) | 1.0 (reference) | 1.0 (reference) | ||
| GT | 121 (34.2) | 107 (35.3) | 1.05 (0.76-1.47) | 0.768 | 1.09 (0.77-1.56) | 0.619 |
| TT | 18 (5.1) | 15 (5.0) | 0.99 (0.49-2.02) | 0.978 | 0.84 (0.38-1.83) | 0.657 |
| GT and TT | 139 (39.3) | 122 (40.3) | 1.04 (0.76-1.43) | 0.794 | 1.06 (0.76-1.48) | 0.743 |
| TT versus others | 18 (5.1) | 15 (5.0) | 0.97 (0.48-1.96) | 0.934 | 0.81 (0.37-1.76) | 0.595 |
| Allele-wise comparison | ||||||
| G | 551 (77.8) | 469 (77.4) | 1.0 (reference) | - | - | |
| T | 157 (22.2) | 137 (22.6) | 1.03 (0.79-1.33) | 0.851 | - | - |
Additionally, when we stratified the analyses by tumor site (Table 3) or sex (Table 4), we found no statistically significant differences in the CaSR gene A986S variant either before or after adjustment for confounding factors. We also conducted a breakdown comparison between cases and controls within different BMI categories (Table 5). In the comparison between normal weight controls and normal weight cases with CRC, as well as in the comparison between overweight/obese controls and overweight/obese cases with CRC, we found no differences between these groups with respect to allele and genotype frequencies of the A986S variant either before or after adjustment for age, sex, smoking status, and family history of CRC.
The Association Between CaSR Gene A986S (Rs1801725) Variant and Risk of Colon and Rectal Cancers After Adjustment for Age, BMI, Sex, Smoking Status, and Family History of Colorectal Cancera
| Variant | Control (N = 354) | Colon (N = 195) | OR (95%CI) | P Value | Control (N = 354) | Rectal (N = 108) | OR (95%CI) | P Value |
|---|---|---|---|---|---|---|---|---|
| rs1801725 G > T | ||||||||
| Genotype-wise comparison | ||||||||
| GG | 215 (60.7) | 113 (57.9) | 1.0 (reference) | 215 (60.7) | 54 (50.0) | 1.0 (reference) | ||
| GT | 121 (34.2) | 74 (37.9) | 1.16 (0.80-1.68) | 0.420 | 121 (34.2) | 43 (39.8) | 1.11 (0.70-1.75) | 0.654 |
| TT | 18 (5.1) | 8 (4.1) | 0.84 (0.35-2.00) | 0.703 | 18 (5.1) | 11 (10.2) | 1.49 (0.69-3.22) | 0.303 |
| GT and TT | 139 (39.3) | 82 (42.0) | 0.98 (0.69-1.39) | 0.928 | 139 (39.3) | 54 (50.0) | 1.17 (0.76-1.80) | 0.471 |
| TT versus others | 18 (5.1) | 8 (4.1) | 1.68 (0.93-3.04) | 0.083 | 18 (5.1) | 11 (10.2) | 1.43 (0.68-3.00) | 0.343 |
| Allele-wise comparison | ||||||||
| G | 551 (77.8) | 278 (71.3) | 1.0 (reference) | 551 (77.8) | 151 (69.9) | 1.0 (reference) | ||
| T | 157 (22.2) | 112 (28.7) | 1.10 (0.84-1.45) | 0.472 | 157 (22.2) | 65 (30.1) | 1.18 (0.84-1.65) | 0.328 |
The Association Between Genotypes and Alleles of CaSR Gene A986S (Rs1801725) Variant and Colorectal Cancer Risk According To Sex Category After Adjustment for Age, BMI, Smoking Status, and Family History of Colorectal Cancera
| Variant | Male | Female | ||||||
|---|---|---|---|---|---|---|---|---|
| Control (No. = 181) | Case (No. = 165) | OR (95%CI) | P Value | Control (No. = 173) | Case (No. = 138) | OR (95%CI) | P Value | |
| rs1801725 G > T | ||||||||
| Genotype-wise comparison | ||||||||
| GG | 99 (54.7) | 88 (53.3) | 1.0 (reference) | 92 (53.2) | 72 (52.2) | 1.0 (reference) | ||
| GT | 72 (39.8) | 60 (36.4) | 1.09 (0.67-1.79) | 0.707 | 65 (37.6) | 49 (35.5) | 1.06 (0.63-1.78) | 0.819 |
| TT | 10 (5.5) | 17 (10.3) | 1.82 (0.73-4.53) | 0.193 | 16 (9.2) | 17 (12.3) | 1.67 (0.76-3.70) | 0.200 |
| GT and TT | 82 (45.3) | 77 (46.7) | 1.19 (0.75-1.90) | 0.450 | 81 (46.8) | 66 (47.8) | 1.18 (0.73-1.90) | 0.494 |
| TT versus others | 10 (5.5) | 17 (10.3) | 1.75 (0.72-4.25) | 0.211 | 16 (9.2) | 17 (12.3) | 1.63 (0.76-3.50) | 0.205 |
| Allele-wise comparison | ||||||||
| G | 270 (74.6) | 236 (71.5) | 1.0 (reference) | 249 (72.0) | 193 (69.9) | 1.0 (reference) | ||
| T | 92 (25.4) | 94 (28.5) | 0.81 (0.59-1.11) | 0.185 | 97 (28.0) | 83 (30.1) | 1.13 (0.81-1.57) | 0.476 |
The Association Between CaSR Gene A986S (Rs1801725) Variant and Colorectal Cancer Risk According To BMI Category After Adjustment for Age, Sex, Smoking Status, and Family History of Colorectal Cancera
| Variant | Normal Weight (BMI < 25 Kg/m2) | Overweight/Obese (BMI ≥ 25 Kg/m2) | ||||||
|---|---|---|---|---|---|---|---|---|
| Control (No. = 180) | Case (No. = 146) | OR (95%CI) | P Value | Control (No. = 174) | Case (No. = 157) | OR (95%CI) | P Value | |
| rs1801725 G > T | ||||||||
| Genotype-wise comparison | ||||||||
| GG | 107 (59.4) | 91 (62.3) | 1.0 (reference) | 108 (62.1) | 90 (57.3) | 1.0 (reference) | ||
| GT | 63 (35.0) | 50 (34.2) | 0.95 (0.57-1.58) | 0.859 | 58 (33.3) | 57 (36.3) | 1.28 (0.78-2.10) | 0.327 |
| TT | 10 (5.6) | 5 (3.4) | 0.52 (0.15-1.81) | 0.311 | 8 (4.6) | 10 (6.4) | 1.14 (0.39-3.33) | 0.805 |
| GT and TT | 73 (40.6) | 55 (37.6) | 0.89 (0.55-1.45) | 0.658 | 66 (37.9) | 67 (42.7) | 1.26 (0.78-2.02) | 0.355 |
| TT versus others | 10 (5.6) | 5 (3.4) | 0.53 (0.15-1.82) | 0.319 | 8 (4.6) | 10 (6.4) | 1.04 (0.36-3.00) | 0.931 |
| Allele-wise comparison | ||||||||
| G | 277 (75.9) | 232 (79.5) | 1.0 (reference) | 274 (78.7) | 237 (75.5) | 1.0 (reference) | ||
| T | 88 (24.4) | 60 (20.5) | 0.81 (0.56-1.18) | 0.278 | 74 (21.3) | 77 (24.5) | 1.20 (0.93-1.73) | 0.319 |
Finally, in this study the risk of obesity in relation to the CaSR gene A986S variant was also examined (data not shown). We observed no significant difference in genotype and allele frequencies between the normal weight cases with CRC and overweight/obese cases with CRC and between normal weight controls and overweight/obese controls for the A986S variant.
4. Discussion
We conducted a case-control study to explore the possible association between the CaSR gene A986S (rs1801725) variant and CRC risk. In the present study, no statistically significant difference was found for this variant in either genotype or allele frequencies between the cases with CRC and the controls and this lack of difference remained non-significant even after adjustment for age, BMI, sex, smoking status, and family history of CRC. Furthermore, no evidence for effect modification of the association A986S variant and CRC by BMI, sex, or tumor site was observed. In addition, the A986S variant was not associated with the risk of obesity in controls and cases with CRC.
4.1. CaSR Gene A986S Variant
Currently, CRC is considered as a complex disease that might result from the interaction between genetic and environmental factors. However, the number and nature of genes that influence susceptibility to CRC are largely unknown. The protective effect of calcium in CRC is well established and is the subject of recent interest. CaSR is an important component of the pathway through which calcium mediates its anticarcinogenic effects on the development of CRC. Calcium can prevent the development of colon cancer directly by inducing apoptosis and differentiation through binding to the CaSR, and indirectly by binding bile acids and free fatty acids (16). It is possible that the changed expression of CaSR is associated with abnormal differentiation and or tumor progression, or both (8). The CaSR expression patterns indicate its role in the pathogenesis of CRC; the expression of CaSR is high in normal large intestinal epithelium, is lower in well-differentiated colon cancer tissue, and is greatly decreased in undifferentiated carcinomas (17, 18). Furthermore, CaSR gene variants appear to be involved in maintaining calcium homeostasis (19). However, the influence of these variants on CaSR protein function is largely unknown up to now. Accordingly, these data support the hypothesis that the CaSR gene variants might have a role in pathogenesis of CRC.
To date, five epidemiological studies (10-14) have evaluated the association between the CaSR gene A986S variant and the risk of colorectal, colon, or rectal cancer. Previous studies have shown that CaSR is a very large gene and the rs1801725 G > T common variant, located in codon 986, resulting in an amino acid shift-alanine (A) or serine (S) - in the intracellular C-terminal tail of the CaSR. This variant (A986S) appears to be involved in maintaining calcium homeostasis and the “T” or “S” allele compared with the “G” or “A” allele was associated with higher circulating calcium and PTH concentrations (19, 20). However, the A986S variant has little functionality despite being highly conserved (11). Studies of the effect of CaSR gene A986S variant on CRC have been inconclusive. Consistent with our findings, most previous studies found no association between this variant and CRC. We did not observe significant associations for the A986S variant in the overall analysis and in the analyses stratified by tumor site, sex, or BMI. In work by Speer et al. (10), the authors reported that there was no association between the A986S variant and rectal cancer risk in a population including 56 cases with rectal cancer and 112 controls. However, they found an association between this variant and more advanced rectal tumors. Another small study (11) that investigated the association between the A986S variant and CRC in 70 cases with CRC and 201 controls could not detect any association between the variant and CRC. On the other hand, Bacsi et al. (12) recently showed that the CaSR A986S “SS” genotype compared with “AA+AS” genotypes was more frequent in 278 cases with CRC than in 260 controls. However, in a large study of 1600 cases with colon cancer and 1949 controls which was conducted by Dong et al. (13) there was no significant association between the A986S variant and colon cancer overall. Their results suggested a possible role of some variants of the CaSR gene on proximal colon cancer, though. Finally, in another large study by Jenab et al. (14) including 1248 cases with CRC and 1248 controls, the A986S variant was not associated with CRC risk.
Inconsistent results such as these are unfortunately common in genetic association studies (21, 22) and discrepancy in these studies may be due to false positive results, differences in the genetic and/or environmental factors triggering the development of CRC, variation in dietary intakes including calcium, small sample size, and statistical methods. Alternatively, the A986S variant may be in linkage disequilibrium with another unknown functional variant of the CaSR gene that explains the discrepancy observed.
4.2. Study Limitations
Although well-designed, this study has several limitations. One limitation is the modest sample size that precludes drawing strong conclusions. Another limitation is that only one variant of the CaSR gene was genotyped and thus coverage of the gene was incomplete. The other limitation is colonoscopy-based study, and the population may not be representative of the general population. Accordingly, we could not completely rule out the possibility of chance findings. Nevertheless, the possibility of true finding should not be excluded.
In conclusion, in this case-control study, the A986S (rs1801725) variant located in exon 7 of CaSR gene not appear to affect the development of CRC in Iranian population. However, studies in other populations are warranted to confirm our findings.
Acknowledgements
References
-
1.
Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54(1):8-29. [PubMed ID: 14974761].
-
2.
Globocan: IARC International Agency for Research on Cancer. Geneva: World Health Organization; Available from: http://globocan.iarc.fr/Default.aspx.
-
3.
Kampman E, Slattery ML, Caan B, Potter JD. Calcium, vitamin D, sunshine exposure, dairy products and colon cancer risk (United States). Cancer Causes Control. 2000;11(5):459-66. [PubMed ID: 10877339].
-
4.
Sesink AL, Termont DS, Kleibeuker JH, Van der Meer R. Red meat and colon cancer: dietary haem-induced colonic cytotoxicity and epithelial hyperproliferation are inhibited by calcium. Carcinogenesis. 2001;22(10):1653-9. [PubMed ID: 11577005].
-
5.
Saidak Z, Mentaverri R, Brown EM. The role of the calcium-sensing receptor in the development and progression of cancer. Endocr Rev. 2009;30(2):178-95. [PubMed ID: 19237714]. https://doi.org/10.1210/er.2008-0041.
-
6.
Hebert SC, Cheng S, Geibel J. Functions and roles of the extracellular Ca2+-sensing receptor in the gastrointestinal tract. Cell Calcium. 2004;35(3):239-47. [PubMed ID: 15200147].
-
7.
Whitfield JF. Calcium, calcium-sensing receptor and colon cancer. Cancer Lett. 2009;275(1):9-16. [PubMed ID: 18725175]. https://doi.org/10.1016/j.canlet.2008.07.001.
-
8.
Chakrabarty S, Radjendirane V, Appelman H, Varani J. Extracellular calcium and calcium sensing receptor function in human colon carcinomas: promotion of E-cadherin expression and suppression of beta-catenin/TCF activation. Cancer Res. 2003;63(1):67-71. [PubMed ID: 12517779].
-
9.
Birchmeier W. E-cadherin as a tumor (invasion) suppressor gene. Bioessays. 1995;17(2):97-9. [PubMed ID: 7748170]. https://doi.org/10.1002/bies.950170203.
-
10.
Speer G, Cseh K, Mucsi K, Takacs I, Dworak O, Winkler G, et al. Calcium-sensing receptor A986S polymorphism in human rectal cancer. Int J Colorectal Dis. 2002;17(1):20-4. [PubMed ID: 12018449].
-
11.
Fuszek P, Lakatos P, Tabak A, Papp J, Nagy Z, Takacs I, et al. Relationship between serum calcium and CA 19-9 levels in colorectal cancer. World J Gastroenterol. 2004;10(13):1890-2. [PubMed ID: 15222030].
-
12.
Bacsi K, Hitre E, Kosa JP, Horvath H, Lazary A, Lakatos PL, et al. Effects of the lactase 13910 C/T and calcium-sensor receptor A986S G/T gene polymorphisms on the incidence and recurrence of colorectal cancer in Hungarian population. BMC Cancer. 2008;8:317. [PubMed ID: 18980667]. https://doi.org/10.1186/1471-2407-8-317.
-
13.
Dong LM, Ulrich CM, Hsu L, Duggan DJ, Benitez DS, White E, et al. Genetic variation in calcium-sensing receptor and risk for colon cancer. Cancer Epidemiol Biomarkers Prev. 2008;17(10):2755-65. [PubMed ID: 18843020]. https://doi.org/10.1158/1055-9965.EPI-08-0388.
-
14.
Jenab M, McKay J, Bueno-de-Mesquita HB, van Duijnhoven FJ, Ferrari P, Slimani N, et al. Vitamin D receptor and calcium sensing receptor polymorphisms and the risk of colorectal cancer in European populations. Cancer Epidemiol Biomarkers Prev. 2009;18(9):2485-91. [PubMed ID: 19706842]. https://doi.org/10.1158/1055-9965.EPI-09-0319.
-
15.
Lorentzon M, Lorentzon R, Lerner UH, Nordstrom P. Calcium sensing receptor gene polymorphism, circulating calcium concentrations and bone mineral density in healthy adolescent girls. Eur J Endocrinol. 2001;144(3):257-61. [PubMed ID: 11248745].
-
16.
Newmark HL, Wargovich MJ, Bruce WR. Colon cancer and dietary fat, phosphate, and calcium: a hypothesis. J Natl Cancer Inst. 1984;72(6):1323-5. [PubMed ID: 6587152].
-
17.
Gama L, Baxendale-Cox LM, Breitwieser GE. Ca2+-sensing receptors in intestinal epithelium. Am J Physiol. 1997;273(4 Pt 1):C1168-75. [PubMed ID: 9357760].
-
18.
Sheinin Y, Kallay E, Wrba F, Kriwanek S, Peterlik M, Cross HS. Immunocytochemical localization of the extracellular calcium-sensing receptor in normal and malignant human large intestinal mucosa. J Histochem Cytochem. 2000;48(5):595-602. [PubMed ID: 10769043].
-
19.
Cole DE, Peltekova VD, Rubin LA, Hawker GA, Vieth R, Liew CC, et al. A986S polymorphism of the calcium-sensing receptor and circulating calcium concentrations. Lancet. 1999;353(9147):112-5. [PubMed ID: 10023897].
-
20.
Marz W, Seelhorst U, Wellnitz B, Tiran B, Obermayer-Pietsch B, Renner W, et al. Alanine to serine polymorphism at position 986 of the calcium-sensing receptor associated with coronary heart disease, myocardial infarction, all-cause, and cardiovascular mortality. J Clin Endocrinol Metab. 2007;92(6):2363-9. [PubMed ID: 17374704]. https://doi.org/10.1210/jc.2006-0071.
-
21.
Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG. Replication validity of genetic association studies. Nat Genet. 2001;29(3):306-9. [PubMed ID: 11600885]. https://doi.org/10.1038/ng749.
-
22.
Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet. 2003;33(2):177-82. [PubMed ID: 12524541]. https://doi.org/10.1038/ng1071.